
E
Tier
Anti-inflammatory tripeptide from the tail of alpha-MSH.
Gut Health Support
Peptide, 3 amino acids
WADA Status:
Not listed
Human Trial Scoreboard
Completed human RCTs
None completed
Largest Human Study
No human studies
Longest exposure
None studied
Most Recent Trial
No completed trial
Description
KPV is the last three amino acids of alpha-MSH, a hormone your body already produces, snipped off and used on its own. The parent hormone has anti-inflammatory effects, and laboratory work suggests this fragment retains some of that activity without the pigmentation effects the full hormone causes. Most of the interest concerns the gut, where cell and animal studies indicate it may calm inflammation in the intestinal lining. That is the entire evidence base. No human trial of any design has been completed, so the step from a promising signal in cultured cells to a benefit in a person with inflammatory bowel disease remains untaken. It is sold widely as a gut-healing treatment, which is a considerable distance ahead of what anyone has actually demonstrated.
What Are The Claims
Claims made for this compound: May calm gut inflammation and support IBD-type conditions (cell and animal); Anti-inflammatory without pigmentation effects; May soothe inflammatory skin conditions (preclinical); Proposed antimicrobial activity
Evidence
The anti-inflammatory mechanism is real in cell and animal models of colitis. Human evidence is absent, and the gut-health claims made for it are extrapolated from those preclinical models.
Evidence Strength
Animal/preclinical only
Caveats
No human trials at all; oral/injectable use entirely off-label and unstudied.
Safety
Alternative Measures
Legal Status
US
Not approved; removed from restricted compounding category April 2026 without approval
UK
Not approved
EU
Not approved
AU
Not approved
WADA
Not listed
Not approved. Research chemical with no completed human trials.
Citations
No verifiable human trial; alpha-MSH C-terminal fragment studied in vitro and in rodent colitis models only.